Company intelligence / Profile preview

Suzhou Southeast Pharmaceuticals

Suzhou, Jiangsu, Chinaszsep.com ↗

Ownership: Private
Development stage: Commercial

Overview

Suzhou Southeast Pharmaceuticals is a China-based pharmaceutical company with a focus on small molecule drug discovery and development. Its pipeline includes preclinical candidates targeting hepatitis C virus NS5 protein and topoisomerase I, with published research demonstrating potent antiproliferative effects of its novel camptothecin derivatives in vitro. No clinical-stage results are available as of the latest data[6].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeProdrug (for camptothecin derivatives)
Industry: Biotech

Drug pipeline

1 asset

TQ-A3326

Partnerships

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Beyond the preview

Go deeper on Suzhou Southeast Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suzhou Southeast Pharmaceuticals.